News

Publication of a preclinical study: Inositol hexakisphosphate kinase (IP6K) is crucial in regulating plasma phosphate levels in vivo, and SCO-006-mediated IP6K inhibition is a potential novel treatment strategy against hyperphosphatemia

Publication of a clinical phase 1 study: SCO-267, a GPR40 full agonist, is safe and well-tolerated, exhibits good potential for once-daily dosing, and improves glycemic control in humans

The clinical results of SCO-267 was presented at the Virtual 81st Scientific Sessions – American Diabetes Association: First report on the clinical data of a GPR40 full agonist in the phase 1 trial

Huadong and SCOHIA PHARMA Announce Strategic Collaboration to Develop, Manufacture and Commercialize SCO-094 in Asia Pacific

SCOHIA initiates a phase 1 study on an SSTR5 antagonist (SCO-240)

Presentation of new preclinical data of GLUT5 inhibitor at the Experimental Biology 2021: GLUT5 inhibition is a novel strategy to treat fructose-induced diseases

Publication of a preclinical study: chronic exposure to SCO-267, a GPR40, is effective in treating diabetes in preclinical models

Publication of a preclinical study: the enteropeptidase inhibitor SCO-792 is therapeutically effective for improving renal function in a nondiabetic rat model of chronic kidney disease

Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, improves obesity via microbiota-driven mechanisms in mice

Conference presentation regarding medicinal chemistry research on a GPR40 full agonist (SCO-267)